Durect Corp., of Cupertino, Calif., signed an agreement with Santen Pharmaceutical Co. Ltd., of Osaka, Japan, granting Santen the exclusive worldwide rights to develop and commercialize a sustained-release product utilizing Durect's Saber technology to deliver an ophthalmology drug.